AHA letter requesting the Biden Administration exercise enforcement discretion with respect to compliance with the Centers for Medicare…
Letter/Comment
Dec 21, 2020
Dec 11, 2020
AHA letter that outlines initial policy priorities for Biden Administration first 100 days.
Jan 30, 2020
AHA comments on the Centers for Medicare & Medicaid Services’ proposed regulation related to Medicaid program financing and supplemental payments.
Jan 31, 2023
January 31, 2023
April Tabor
Secretary Federal Trade Commission
600 Pennsylvania Avenue NW
Suite CC-5610 (Annex C)
Washington, DC 20580
Re: Notice of Proposed Rulemaking, Federal Trade Commission; Non-Compete Clause Rule; 88 Fed. Reg. 3482 (RIN: 3084-AB74) (January 19, 2023)
Dear Ms. Tabor:
Jan 30, 2023
AHA comments on the CMS’ Request for Information on Essential Health Benefits (EHB).
Jan 30, 2023
AHA comments on the CMS' proposed Notice of Benefit and Payment Parameters for 2024.
Jan 30, 2023
AHA provides feedback to the Senate on the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) Act, and to support Congress’ continued efforts to transform health care through permanent telehealth reform.
Jan 30, 2023
AHA provides feedback on the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) Act, and to support Congress’ continued efforts to transform health care through permanent telehealth reform
Jan 30, 2023
AHA comments proposed revisions to the regulations governing the confidentiality of substance use disorder (SUD) records, commonly known as 42 CFR Part 2 (“Part 2”).
Jan 27, 2023
January 27, 2023
Emeka Egwim, PharmD, RPh LCDR
U.S. Public Health Service Director
Office of Pharmacy Affairs
Health Resources and Services Administration 5600 Fishers Lane, 08W05A
Rockville, MD 20857
RE: HRSA 340B Drug Pricing Program; Administrative Dispute Resolution Proposed Rule, HHS Docket…